Limits...
Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes.

Mizushige T, Kobori H, Nishijima Y, Yano Y, Sakata K, Hayakawa M, Nishiyama A - J Diabetes Res (2015)

Bottom Line: Alogliptin treatment tended to decrease UAlbCR (99.6 ± 26.8 versus 114.6 ± 36.0 mg/g Cr, P = 0.198).When all patients were redivided into two groups, those with higher values of UAGTCR before the treatment (Group H, n = 20) and those with lower values (Group L), Group H showed significantly decreased UAlbCR in response to alogliptin (-14.6 ± 8.6 versus +22.8 ± 16.8%, P = 0.033).Urinary AGT could be a prognostic marker of renoprotective effects of alogliptin in patients with T2D.

View Article: PubMed Central - PubMed

Affiliation: Kagawa University School of Medicine, Kagawa 761-0793, Japan ; Jichi Medical University School of Medicine, Tochigi, Japan.

ABSTRACT

Background: The aims of this study were (1) to examine the renoprotective effects of alogliptin and (2) to establish urinary angiotensinogen (AGT) as a prognostic marker of renoprotective effects of alogliptin in patients with type 2 diabetes (T2D).

Methods: In 43 patients with T2D (18 women, 66.1 ± 1.71 years), 25 mg/day of alogliptin was added to the traditional hypoglycemic agents and/or nondrug treatments. Urinary concentrations of albumin (Alb) and AGT, normalized by urinary concentrations of creatinine (Cr) (UAlbCR and UAGTCR, respectively), were measured before and after the 12-week alogliptin treatment.

Results: Alogliptin treatment tended to decrease UAlbCR (99.6 ± 26.8 versus 114.6 ± 36.0 mg/g Cr, P = 0.198). Based on % change in UAlbCR, patients were divided into two groups, responders (< -25%) and nonresponders (≥ -25%), and a logistic analysis of UAGTCR before treatment showed cutoff value of 20.8 µg/g Cr. When all patients were redivided into two groups, those with higher values of UAGTCR before the treatment (Group H, n = 20) and those with lower values (Group L), Group H showed significantly decreased UAlbCR in response to alogliptin (-14.6 ± 8.6 versus +22.8 ± 16.8%, P = 0.033).

Conclusion: Urinary AGT could be a prognostic marker of renoprotective effects of alogliptin in patients with T2D.

No MeSH data available.


Related in: MedlinePlus

Logistic analysis of urinary concentrations of angiotensinogen normalized by urinary concentrations of creatinine (UAGTCR) before treatment. Good responders to the alogliptin treatment were defined in terms of % change in urinary concentrations of Alb normalized by urinary concentrations of creatinine less than −25% after the 12-week treatment, and a logistic analysis of UAGTCR before treatment showed the area under the curve as 0.644. When we set the cutoff value of UAGTCR as 20.8 μg/g Cr, the maximum specificity (17/27 = 63.0%) and sensitivity (10/16 = 62.5%) were obtained (Youden index = 0.255).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4562181&req=5

fig2: Logistic analysis of urinary concentrations of angiotensinogen normalized by urinary concentrations of creatinine (UAGTCR) before treatment. Good responders to the alogliptin treatment were defined in terms of % change in urinary concentrations of Alb normalized by urinary concentrations of creatinine less than −25% after the 12-week treatment, and a logistic analysis of UAGTCR before treatment showed the area under the curve as 0.644. When we set the cutoff value of UAGTCR as 20.8 μg/g Cr, the maximum specificity (17/27 = 63.0%) and sensitivity (10/16 = 62.5%) were obtained (Youden index = 0.255).

Mentions: Patients were divided into two groups: those for whom UAlbCR decreased less than 25% and those for whom it decreased more than 25%. A logistic analysis of UAGTCR before treatment showed AUC as 0.644. When we set the cutoff value of UAGTCR as 20.8 μg/g Cr, the maximum specificity (17/27 = 63.0%) and sensitivity (10/16 = 62.5%) were obtained (Youden index = 0.255, Figures 2(a) and 2(b)).


Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes.

Mizushige T, Kobori H, Nishijima Y, Yano Y, Sakata K, Hayakawa M, Nishiyama A - J Diabetes Res (2015)

Logistic analysis of urinary concentrations of angiotensinogen normalized by urinary concentrations of creatinine (UAGTCR) before treatment. Good responders to the alogliptin treatment were defined in terms of % change in urinary concentrations of Alb normalized by urinary concentrations of creatinine less than −25% after the 12-week treatment, and a logistic analysis of UAGTCR before treatment showed the area under the curve as 0.644. When we set the cutoff value of UAGTCR as 20.8 μg/g Cr, the maximum specificity (17/27 = 63.0%) and sensitivity (10/16 = 62.5%) were obtained (Youden index = 0.255).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4562181&req=5

fig2: Logistic analysis of urinary concentrations of angiotensinogen normalized by urinary concentrations of creatinine (UAGTCR) before treatment. Good responders to the alogliptin treatment were defined in terms of % change in urinary concentrations of Alb normalized by urinary concentrations of creatinine less than −25% after the 12-week treatment, and a logistic analysis of UAGTCR before treatment showed the area under the curve as 0.644. When we set the cutoff value of UAGTCR as 20.8 μg/g Cr, the maximum specificity (17/27 = 63.0%) and sensitivity (10/16 = 62.5%) were obtained (Youden index = 0.255).
Mentions: Patients were divided into two groups: those for whom UAlbCR decreased less than 25% and those for whom it decreased more than 25%. A logistic analysis of UAGTCR before treatment showed AUC as 0.644. When we set the cutoff value of UAGTCR as 20.8 μg/g Cr, the maximum specificity (17/27 = 63.0%) and sensitivity (10/16 = 62.5%) were obtained (Youden index = 0.255, Figures 2(a) and 2(b)).

Bottom Line: Alogliptin treatment tended to decrease UAlbCR (99.6 ± 26.8 versus 114.6 ± 36.0 mg/g Cr, P = 0.198).When all patients were redivided into two groups, those with higher values of UAGTCR before the treatment (Group H, n = 20) and those with lower values (Group L), Group H showed significantly decreased UAlbCR in response to alogliptin (-14.6 ± 8.6 versus +22.8 ± 16.8%, P = 0.033).Urinary AGT could be a prognostic marker of renoprotective effects of alogliptin in patients with T2D.

View Article: PubMed Central - PubMed

Affiliation: Kagawa University School of Medicine, Kagawa 761-0793, Japan ; Jichi Medical University School of Medicine, Tochigi, Japan.

ABSTRACT

Background: The aims of this study were (1) to examine the renoprotective effects of alogliptin and (2) to establish urinary angiotensinogen (AGT) as a prognostic marker of renoprotective effects of alogliptin in patients with type 2 diabetes (T2D).

Methods: In 43 patients with T2D (18 women, 66.1 ± 1.71 years), 25 mg/day of alogliptin was added to the traditional hypoglycemic agents and/or nondrug treatments. Urinary concentrations of albumin (Alb) and AGT, normalized by urinary concentrations of creatinine (Cr) (UAlbCR and UAGTCR, respectively), were measured before and after the 12-week alogliptin treatment.

Results: Alogliptin treatment tended to decrease UAlbCR (99.6 ± 26.8 versus 114.6 ± 36.0 mg/g Cr, P = 0.198). Based on % change in UAlbCR, patients were divided into two groups, responders (< -25%) and nonresponders (≥ -25%), and a logistic analysis of UAGTCR before treatment showed cutoff value of 20.8 µg/g Cr. When all patients were redivided into two groups, those with higher values of UAGTCR before the treatment (Group H, n = 20) and those with lower values (Group L), Group H showed significantly decreased UAlbCR in response to alogliptin (-14.6 ± 8.6 versus +22.8 ± 16.8%, P = 0.033).

Conclusion: Urinary AGT could be a prognostic marker of renoprotective effects of alogliptin in patients with T2D.

No MeSH data available.


Related in: MedlinePlus